SESSION 2 – Systemic treatment and metastatic disease
ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities
Date
15 Oct 2020Session
SESSION 2 – Systemic treatment and metastatic diseasePresenters
S. Gillessen, CHResources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Participants Clinical Case Discussion: From mCSPC o mCRPC: when a Novel Hormonal Agent makes the difference
Presenter: F. Paolieri, IT
Session: SESSION 2 – Systemic treatment and metastatic disease
Resources:
Slides
Webcast
Immunotherapy and other new treatments (including DNA repair)
Presenter: K. Fizazi, FR
Session: SESSION 2 – Systemic treatment and metastatic disease
Resources:
Slides
Webcast
Chemotherapy (taxanes and platins) and Radium-223, mechanism of action, main efficacy results in Castration-Resistant Prostate Cancer (CRPC) and toxicities
Presenter: G. Attard, UK
Session: SESSION 2 – Systemic treatment and metastatic disease
Resources:
Slides
Webcast
Bone health agents, mechanism of action, efficacy and toxicities
Presenter: K. Fizazi, FR
Session: SESSION 2 – Systemic treatment and metastatic disease
Resources:
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.